In the litigation over alleged illegal pricing tactics used in marketing the prostate cancer drug Lupron, the fate of hundreds of plaintiffs remains unclear despite a federal judge's approval earlier this month of $150 million in settlements.
And complicating the claims of nearly all of the so-called "opt-out" plaintiffs is the fact that their lawyers at the Philadelphia firm Kline & Specter were harshly criticized by the judge for their marketing tactics.
In his May 12 decision, U.S. District Judge Richard G. Stearns of the District of Massachusetts faulted Kline & Specter for launching a pair of Internet Web sites that, Stearns said, were "intended to mislead potential members of the [federal multi-district litigation] MDL class."
It gets much worse than that -- especially toward the end of the article. Details here from The Legal Intelligencer via Law.com.